TT-00420/Atezolizumab

N/A

Report date: 2024/02/05 16:47:11

Base Information

Drug NameTT-00420/Atezolizumab

Drug Alias NameN/A

ClassificationBiologics

Mechanisms of ActionProgrammed death-ligand 1 blockersSerine/threonine-protein kinase Aurora-A inhibitorsSerine/threonine-protein kinase Aurora-B inhibitors +[8]

TargetsProgrammed death-ligand 1Serine/threonine-protein kinase Aurora-ASerine/threonine-protein kinase Aurora-B +[8]

Therapy Area/IndicationsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsYes Tinengotinib Atezolizumab

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesTransThera Sciences (Nanjing) Inc

China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd TransThera Sciences (Nanjing) Inc

Inactive CompaniesN/A

Active IndicationsGastrointestinal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A